257 related articles for article (PubMed ID: 33008404)
1. Long-term outcomes of moderately hypofractionated radiotherapy (67.5 Gy in 25 fractions) for prostate cancer confined to the pelvis: a single center retrospective analysis.
Yao L; Shou J; Wang S; Song Y; Fang H; Lu N; Tang Y; Chen B; Qi S; Yang Y; Jing H; Jin J; Yu Z; Li Y; Liu Y
Radiat Oncol; 2020 Oct; 15(1):231. PubMed ID: 33008404
[TBL] [Abstract][Full Text] [Related]
2. Ten-Year Outcomes of Moderately Hypofractionated (70 Gy in 28 fractions) Intensity Modulated Radiation Therapy for Localized Prostate Cancer.
Abu-Gheida I; Reddy CA; Kotecha R; Weller MA; Shah C; Kupelian PA; Mian O; Ciezki JP; Stephans KL; Tendulkar RD
Int J Radiat Oncol Biol Phys; 2019 Jun; 104(2):325-333. PubMed ID: 30721720
[TBL] [Abstract][Full Text] [Related]
3. Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5-year outcomes of the HYPO-RT-PC randomised, non-inferiority, phase 3 trial.
Widmark A; Gunnlaugsson A; Beckman L; Thellenberg-Karlsson C; Hoyer M; Lagerlund M; Kindblom J; Ginman C; Johansson B; Björnlinger K; Seke M; Agrup M; Fransson P; Tavelin B; Norman D; Zackrisson B; Anderson H; Kjellén E; Franzén L; Nilsson P
Lancet; 2019 Aug; 394(10196):385-395. PubMed ID: 31227373
[TBL] [Abstract][Full Text] [Related]
4. Moderately Hypofractionated Radiotherapy in Node-positive Prostate Cancer.
Mallick I; Das A; Arunsingh M
Clin Oncol (R Coll Radiol); 2019 Apr; 31(4):260-264. PubMed ID: 30718087
[TBL] [Abstract][Full Text] [Related]
5. Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): late toxicity results from a randomised, non-inferiority, phase 3 trial.
Aluwini S; Pos F; Schimmel E; Krol S; van der Toorn PP; de Jager H; Alemayehu WG; Heemsbergen W; Heijmen B; Incrocci L
Lancet Oncol; 2016 Apr; 17(4):464-474. PubMed ID: 26968359
[TBL] [Abstract][Full Text] [Related]
6. Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): acute toxicity results from a randomised non-inferiority phase 3 trial.
Aluwini S; Pos F; Schimmel E; van Lin E; Krol S; van der Toorn PP; de Jager H; Dirkx M; Alemayehu WG; Heijmen B; Incrocci L
Lancet Oncol; 2015 Mar; 16(3):274-83. PubMed ID: 25656287
[TBL] [Abstract][Full Text] [Related]
7. Safety of accelerated hypofractionated whole pelvis radiation therapy prior to high dose rate brachytherapy or stereotactic body radiation therapy prostate boost.
Phuong C; Chan JW; Ni L; Wall P; Mohamad O; Wong AC; Hsu IC; Chang AJ
Radiat Oncol; 2022 Jan; 17(1):12. PubMed ID: 35057827
[TBL] [Abstract][Full Text] [Related]
8. Hypofractionated radiation therapy (66 Gy in 22 fractions at 3 Gy per fraction) for favorable-risk prostate cancer: long-term outcomes.
Patel N; Faria S; Cury F; David M; Duclos M; Shenouda G; Ruo R; Souhami L
Int J Radiat Oncol Biol Phys; 2013 Jul; 86(3):534-9. PubMed ID: 23597418
[TBL] [Abstract][Full Text] [Related]
9. Long-term outcome of a moderately hypofractionated, intensity-modulated radiotherapy approach using an endorectal balloon for patients with localized prostate cancer.
Teh BS; Lewis GD; Mai W; Pino R; Ishiyama H; Butler EB
Cancer Commun (Lond); 2018 Apr; 38(1):11. PubMed ID: 29764515
[TBL] [Abstract][Full Text] [Related]
10. The 5-year outcomes of moderately hypofractionated radiotherapy (66 Gy in 22 fractions, 3 fractions per week) for localized prostate cancer: a retrospective study.
Hashimoto Y; Motegi A; Akimoto T; Mitsuhashi N; Iizuka J; Tanabe K; Ishii Y; Kono S; Izumi S; Karasawa K
Int J Clin Oncol; 2018 Feb; 23(1):165-172. PubMed ID: 28758177
[TBL] [Abstract][Full Text] [Related]
11. Hypofractionated versus conventionally fractionated radiotherapy for patients with localised prostate cancer (HYPRO): final efficacy results from a randomised, multicentre, open-label, phase 3 trial.
Incrocci L; Wortel RC; Alemayehu WG; Aluwini S; Schimmel E; Krol S; van der Toorn PP; Jager H; Heemsbergen W; Heijmen B; Pos F
Lancet Oncol; 2016 Aug; 17(8):1061-1069. PubMed ID: 27339116
[TBL] [Abstract][Full Text] [Related]
12. Acute and Late Toxicity after Moderate Hypofractionation with Simultaneous Integrated Boost (SIB) Radiation Therapy for Prostate Cancer. A Single Institution, Prospective Study.
Jorgo K; Polgar C; Major T; Stelczer G; Herein A; Pocza T; Gesztesi L; Agoston P
Pathol Oncol Res; 2020 Apr; 26(2):905-912. PubMed ID: 30888646
[TBL] [Abstract][Full Text] [Related]
13. Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial.
Dearnaley D; Syndikus I; Mossop H; Khoo V; Birtle A; Bloomfield D; Graham J; Kirkbride P; Logue J; Malik Z; Money-Kyrle J; O'Sullivan JM; Panades M; Parker C; Patterson H; Scrase C; Staffurth J; Stockdale A; Tremlett J; Bidmead M; Mayles H; Naismith O; South C; Gao A; Cruickshank C; Hassan S; Pugh J; Griffin C; Hall E;
Lancet Oncol; 2016 Aug; 17(8):1047-1060. PubMed ID: 27339115
[TBL] [Abstract][Full Text] [Related]
14. Moderately Hypofractionated Helical Tomotherapy for Prostate Cancer: Ten-year Experience of a Mono-institutional Series of 415 Patients.
Cozzi S; Ruggieri MP; Alì E; Ghersi SF; Vigo F; Augugliaro M; Giaccherini L; Iori F; Najafi M; Bardoscia L; Botti A; Trojani V; Ciammella P; Iotti C
In Vivo; 2023; 37(2):777-785. PubMed ID: 36881094
[TBL] [Abstract][Full Text] [Related]
15. Short-term androgen suppression and radiotherapy versus intermediate-term androgen suppression and radiotherapy, with or without zoledronic acid, in men with locally advanced prostate cancer (TROG 03.04 RADAR): 10-year results from a randomised, phase 3, factorial trial.
Denham JW; Joseph D; Lamb DS; Spry NA; Duchesne G; Matthews J; Atkinson C; Tai KH; Christie D; Kenny L; Turner S; Gogna NK; Diamond T; Delahunt B; Oldmeadow C; Attia J; Steigler A
Lancet Oncol; 2019 Feb; 20(2):267-281. PubMed ID: 30579763
[TBL] [Abstract][Full Text] [Related]
16. Four-Year Outcomes From a Prospective Phase II Clinical Trial of Moderately Hypofractionated Proton Therapy for Localized Prostate Cancer.
Grewal AS; Schonewolf C; Min EJ; Chao HH; Both S; Lam S; Mazzoni S; Bekelman J; Christodouleas J; Vapiwala N
Int J Radiat Oncol Biol Phys; 2019 Nov; 105(4):713-722. PubMed ID: 31199994
[TBL] [Abstract][Full Text] [Related]
17. "Give me five" ultra-hypofractionated radiotherapy for localized prostate cancer: non-invasive ablative approach.
Marvaso G; Riva G; Ciardo D; Gandini S; Fodor C; Zerini D; Colangione SP; Timon G; Comi S; Cambria R; Cattani F; De Cobelli O; Orecchia R; Jereczek-Fossa BA
Med Oncol; 2018 May; 35(6):96. PubMed ID: 29748830
[TBL] [Abstract][Full Text] [Related]
18. Moderately Hypofractionated Radiotherapy and Androgen Deprivation Therapy for High-risk Localised Prostate Cancer: Predictors of Long-term Biochemical Control and Toxicity.
Maulik S; Arunsingh M; Arun B; Prasath S; Mallick I
Clin Oncol (R Coll Radiol); 2022 Jan; 34(1):e52-e60. PubMed ID: 34456107
[TBL] [Abstract][Full Text] [Related]
19. Hypofractionated external beam radiotherapy to boost the prostate with ≥85 Gy/equivalent dose for patients with localised disease at high risk of lymph node involvement: feasibility, tolerance and outcome.
Zilli T; Jorcano S; Escudé L; Linero D; Rouzaud M; Dubouloz A; Miralbell R
Clin Oncol (R Coll Radiol); 2014 Jun; 26(6):316-22. PubMed ID: 24667210
[TBL] [Abstract][Full Text] [Related]
20. Hypofractionated Volumetric Modulated Arc Radiotherapy with simultaneous Elective Nodal Irradiation is feasible in prostate cancer patients: A single institution experience.
Hegazy MW; Mahmood RI; Al Otaibi MF; Khalil EM
J Egypt Natl Canc Inst; 2016 Jun; 28(2):101-10. PubMed ID: 27133975
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
